SIR TECHNOLOGY - THE EFFECTIVE COMBINATION
SIROLIMUS CONTROLLED ELUTION
- Antiproliferative action
- Reduction of inflammatory response
- 1.4 µg / mm² of Abluminal Stent surface
- 85% eluted at 48 days (in average*)
Elution Profile window perfectly adapted to prevent natural adverse effects of healing process
* data on file
BIODEGRADABLE POLYMER
- Simultaneous polymer biodegradation and drug elution
- Nearly complete resorption expected within 180 days*
-
Protective layer to prevent initial
burst effect of Sirolimus - Fully degraded and metabolized
-
Complete reversion to BMS expected
within 180 days*
* data on file
Abluminal Coating
- Combination with Thin Strut design for faster healing
- Limited luminal polymer exposure
- Reduced systemic exposure
- Reduced risk of delayed healing
- Early BMS-like endothelial coverage expected
PRE-CLINICAL EVALUATION
Histological section at 90 days
after implantation *
At 180 days, demonstration of
- Absence of inflammatory response
- Nearly complete polymer absorption
* data on file